Protara Therapeutics, Inc. — Director's Dealing 2020

Jan 13, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ArTara Therapeutics, Inc. (TARA)
CIK: 0001359931
Period of Report: 2020-01-09

Reporting Person: Opaleye, L.P. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-01-09	Common Stock	A	777635	—	Acquired	782238	Direct
2020-01-09	Common Stock	A	1426234	$7.01	Acquired	2208472	Direct

Footnotes

F1: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly-owned subsidiary of the Issuer.

F2: These shares were received in exchange for: i) 571,428 shares of ArTara Sub common stock; and ii) 3,505,174 shares of ArTara Sub exchangeable common stock, in connection with the merger.